Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients

The Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation of the impac...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancers 2020-03, Vol.12 (4), p.808
Hauptverfasser:	Fiala, Ondrej, Finek, Jindrich, Poprach, Alexandr, Melichar, Bohuslav, Kopecký, Jindrich, Zemanova, Milada, Kopeckova, Katerina, Mlcoch, Tomas, Dolezal, Tomas, Capkova, Lenka, Buchler, Tomas
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical medicine Clinical trials Confidence intervals Cytokines Hemoglobin Kidney cancer Laboratories Metastases Metastasis Patients Renal cell carcinoma Risk factors Risk groups Software Survival analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!